The Invisible Architecture of the Medicine Cabinet: Europe’s Capsule, Blister, and API Industries in Transformation

Before a tablet reaches a patient, it passes through a supply chain of extraordinary complexity and near-total invisibility. The gelatin or cellulose shell that encases the active ingredient. The transparent or aluminium-laminated blister cavity that holds it. The vitamin or synthetic molecule that constitutes the therapeutic payload. These three product categories — empty hard capsules, pharmaceutical blister film, and active pharmaceutical ingredients — are the unglamorous infrastructure of modern medicine: industrially produced at scale, governed by some of the most demanding quality regulations in any manufacturing sector, and sourced, increasingly, from a geography that European policymakers have spent the past five years trying to reduce their dependence on.

Together, these three segments represent a European market of approximately $60 billion — dominated at the supply end by a handful of consolidating Western groups and, at the commodity tier, by Chinese and Indian manufacturers whose cost competitiveness has systematically displaced European producers over the past three decades. Understanding their history, their current competitive dynamics, and the forces reshaping them toward 2030 is essential for any company operating in pharmaceutical manufacturing, nutraceutical production, contract packaging, or the supply chains that serve them.

The origins of a dosage form. The hard-shell capsule was invented in 1833 by Parisian pharmacist François Mothès, who developed the gelatin cap to mask the unpleasant taste of medicines. What began as an individual practitioner’s innovation was industrialised at scale in the United States from the 1870s onward, with Parke-Davis — later Warner-Lambert, then Pfizer — among the first major commercial producers. By the mid-twentieth century, the two-piece hard gelatin capsule (HGC) had become the standard pharmaceutical dosage form across most therapeutic categories, valued for its versatility: it accommodates powders, pellets, granules, mini-tablets, and liquids within a single standardised shell. European pharmaceutical companies adopted hard capsule technology widely from the 1950s onward, with dedicated sites in Germany, France, Spain, Italy, and the UK.

The pivotal modern disruption was the introduction of hydroxypropyl methylcellulose (HPMC) capsules in the 1990s. HPMC is a plant-derived polymer that resolves three structural limitations of gelatin: it is suitable for strict vegetarians and for patients with religious dietary restrictions (Halal and Kosher); it does not interact with oxygen-sensitive formulations; and it is less susceptible to brittleness in low-humidity environments. Qualicaps, then a Shionogi subsidiary, commercialised the first HPMC two-piece capsule under the Quali-V brand in 1999. Lonza’s Capsugel division followed with Vcaps and Vcaps Plus. HPMC capsules commanded a price premium of 30 to 60% over comparable gelatin capsules but found an immediate market in premium nutraceuticals and in pharmaceutical formulations where gelatin cross-linking or moisture sensitivity was a concern.

The 2010s brought a second wave of product innovation: enteric HPMC capsules for targeted intestinal delivery, liquid-filled hard capsules (LFHCs), and acid-resistant delayed-release (DR) formats. These speciality segments now represent a fast-growing niche above the commodity capsule market, and their growth is disproportionately concentrated in the nutraceutical and functional food sector, where consumer willingness to pay for "clean label," "vegan," and "allergen-free" positioning has created pricing power that the pharmaceutical sector’s cost pressure does not permit.

The market in 2024: size, structure, and the pricing disruption. The European empty hard capsule market was worth approximately USD 380–412 million in 2024, representing roughly 13 to 15% of the global market of approximately USD 2.8–3.1 billion. Growth is running at a compound annual rate of 6 to 9%, with the HPMC segment growing faster — at approximately 9.2% annually — as the structural shift away from gelatin accelerates. By 2030, HPMC is forecast to account for 30 to 35% of European hard capsule volume, up from approximately 25% today.

Within Europe, consumption is heavily concentrated in the pharmaceutical manufacturing sector (approximately 70 to 75% of volume), with the nutraceutical and food supplement sector accounting for the remainder and growing proportionally faster. Italy — Europe’s largest dietary supplement market, accounting for approximately 18% of EU supplement consumption — grows at 5 to 7% annually. Germany, France, Spain, and the UK follow as the principal consumption markets. The competitive environment in early 2026, however, is under sharp pricing pressure. A February 2026 Kline Group market intelligence brief characterised European hard capsule prices as "historically low," attributing the compression to the aggressive entry of Chinese and Indian manufacturers who have invested heavily in EU GMP certification. Certification has been the primary market-access barrier for Asian suppliers — there are no anti-dumping duties on empty capsule imports into the EU — and as that barrier is progressively overcome, the pricing dynamics of a cost-competitive Asian supply base are beginning to reach the European market.

The supplier consolidation story: from Pfizer to private equity to strategic buyers. Capsugel — the world’s largest capsule manufacturer — originated as a division of Parke-Davis, passing through Warner-Lambert and then Pfizer. In 2011, KKR acquired it in a USD 2.38 billion transaction. Lonza Group (Switzerland) then acquired Capsugel for USD 5.5 billion in 2017, integrating it into its broader CDMO platform. In 2026, Lonza announced the divestiture of Capsugel to Lone Star Funds for approximately USD 3 billion — the strategic rationale being Lonza’s decision to concentrate on biologics and high-science pharmaceutical development. Post-divestiture, Capsugel/Lonza Consumer Health holds approximately 44% of the global HPMC capsule market.

Qualicaps was founded in 1994 as a Shionogi (Japan) subsidiary to commercialise HPMC capsule technology. It passed through Carlyle Group and Mitsubishi Chemical before being acquired by Roquette Frères (France) in October 2023. Roquette — the world’s largest plant-based ingredient group — owns Qualicaps alongside its plant-based starch and excipient portfolio. Qualicaps operates its European manufacturing headquarters in Alcobendas, Spain.

The most significant structural development among Asian manufacturers is the emergence of an Indian nearshoring strategy. At least one major Indian capsule group — among the world’s three largest by volume — has invested over EUR 50 million in a greenfield manufacturing facility inside the EU during 2022–2023, establishing wholly-owned European production to supply CDMOs and generics companies with competitively priced capsules manufactured under EU GMP. The Chinese dimension is characterised by scale that is difficult to appreciate from a European perspective: China hosts more than 13 capsule manufacturers with individual annual capacities exceeding 10 billion capsules, several of which have achieved EU GMP and CEP certifications. The regulatory challenge for Chinese suppliers is real — EDQM inspection data suggests approximately 60% non-compliance among re-inspected Chinese API and excipient facilities — but the suppliers who successfully navigate EU GMP certification gain access to a large, premium-priced market, and the pressure on European incumbents’ pricing is then immediate and structural.

A technology born from oral contraceptives and the Tylenol crisis. Blister packaging for pharmaceuticals traces its origins to the early 1960s, when PVC thermoforming technology was first applied to the packaging of oral contraceptives — a product category where precise daily dose counting and tamper-evidence were commercially important. Commercialisation at scale followed through the late 1960s and 1970s. German and Italian pharmaceutical companies were early adopters, and both countries developed strong equipment and film supply chains that remain at the heart of the global industry today. Machines from IMA (Bologna), Uhlmann (Laupheim, Germany), and Marchesini (Bologna) became the global standard for blister packaging lines — a competitive position in equipment manufacturing that Europe has maintained while progressively ceding ground in the materials themselves.

The 1982 Tylenol tampering crisis in the United States — though American-centred — reverberated globally and cemented tamper-evidence as a non-negotiable pharmaceutical packaging requirement, accelerating the adoption of aluminium lidding foil as the heat-seal layer. Cold-form (Alu-Alu) technology was developed through the 1980s and 1990s for moisture- and oxygen-sensitive products. The EU’s Falsified Medicines Directive (FMD, Directive 2011/62/EU), implemented from February 2019, introduced mandatory serialisation and tamper-evident features, driving a capital expenditure wave across European packaging lines that continues to reverberate — smaller CDMOs and contract packagers are now replacing ageing blister lines with modern units integrating vision systems, reject mechanisms, and serialisation printers.

The market in 2024–2025: a EUR 5 billion category under structural transition. The European pharmaceutical blister market was valued at approximately USD 4.74–4.76 billion in 2024 and USD 5.08 billion in 2025, forecast to reach USD 7.0–7.1 billion by 2030 at a CAGR of approximately 6.8%. Blister packaging accounts for 70 to 80% of all solid oral dosage form (OSD) pharmaceutical packaging in Europe.

The materials landscape encompasses three principal systems. PVC thermoformed film remains the legacy standard: low cost, excellent thermoformability, clarity, and accumulated regulatory history. Its barrier properties are modest, typically augmented by PVDC coating or acrylic lamination. High-barrier thermoformable films — PVDC-coated PVC and Aclar (polychlorotrifluoroethylene, produced by Honeywell) — offer significantly better moisture and oxygen barrier at several times the price of standard PVC. Cold-form Alu-Alu laminates — typically OPA (oriented polyamide) / aluminium foil / PVC, cold-pressed without heat — offer essentially zero moisture vapour transmission and are the fastest-growing segment, expanding at approximately 6% annually. The cold-form growth is driven simultaneously by the expansion of biologics-related oral products demanding Alu-Alu protection and by CEE generics manufacturing of complex APIs in cardiovascular, CNS, and oncology categories that require high-barrier packaging.

The aluminium foil question. A commercial variable of immediate significance is the status of EU anti-dumping duties on Chinese aluminium converter foil — the material used for heat-seal lidding in blister packs. The EU imposed duties of 15.4 to 28.5% on Chinese aluminium converter foil in December 2021 for a five-year term. Those duties expire in December 2026, and the renewal decision — requiring a standard "expiry review" investigation — was not concluded at the time of writing. Any expiry without renewal would remove a meaningful cost disadvantage from Chinese foil exporters, creating renewed price competition for European and Japanese lidding foil producers and potentially benefiting downstream blister film converters and pharmaceutical packagers through lower input costs.

Supplier dynamics: concentration, a financial crisis, and sustainability ambitions. The pharmaceutical blister film supply industry is highly concentrated. Amcor (Switzerland/Australia, NYSE: AMCR) is the world’s largest pharmaceutical flexible packaging company, generating revenue of approximately USD 14 billion globally across all packaging categories, and is investing in recyclable blister film formats. Klöckner Pentaplast (Germany/Luxembourg), a leading European supplier of PVC and specialty rigid films including pharma blister substrates, completed a EUR 1.3 billion debt-for-equity conversion in 2026 — in effect a restructuring equivalent to Chapter 11 for its US operations — while maintaining EU operations. This financial stress has raised questions among pharmaceutical customers about supply security and created commercial opportunities for competitors positioned to offer continuity assurance. Beyond these two, the market includes specialised European and Swiss film converters serving high-barrier applications, as well as Austrian and multinational suppliers strong in aluminium lidding formats — a tier that rewards reliability and specification consistency as much as price.

The sustainability dimension deserves specific attention. The EU Packaging and Packaging Waste Regulation (PPWR), adopted in 2025 with phased implementation from August 2026, introduces recyclability requirements across packaging categories. PVC/aluminium composite blisters are structurally difficult to recycle — the laminate structure that creates their barrier properties also prevents the material separation that recycling requires. Under PPWR, pharmaceutical packaging in direct contact with medicinal products is classified as contact-sensitive and is currently exempted from primary recyclability targets until a review scheduled for 2035. This exemption provides breathing room but does not remove pressure from pharmaceutical companies’ own ESG commitments: AstraZeneca, Bayer, Novartis, and Roche have all published packaging sustainability roadmaps targeting reduction or elimination of PVC in primary packaging by 2030–2035. The industry will remain predominantly PVC/aluminium through 2030; the transition will follow, not precede, the regulatory review.

How Europe lost its chemistry advantage. European pharmaceutical chemistry dominated global API production through most of the twentieth century. The continent that gave the world aspirin (Bayer, 1899), sulfonamides (Bayer/IG Farben, 1930s), and penicillin industrial production (UK, 1940s) was the original centre of pharmaceutical active ingredient synthesis. Clusters in Germany (Rhine Valley, Bavaria), Switzerland (Basel — the Novartis/Sandoz/Roche triangle), and the UK defined the global competitive landscape through the 1980s.

The shift away from European API manufacturing began in earnest in the 1990s and accelerated through the 2000s under three converging forces: dramatically lower labour and environmental compliance costs in China and India; the generic wave following Waxman-Hatch (US, 1984) and equivalent European frameworks, which put intense price pressure on drug manufacturers; and the unbundling of vertically integrated pharmaceutical companies, who sold off chemical manufacturing assets. By the late 2010s, approximately 72% of APIs used in European drug production were imported, the majority from China and India. Vitamin C APIs — once produced by Roche, Merck KGaA, and BASF in Europe — migrated almost entirely to China, which now accounts for approximately 80% of global Vitamin C production. Europe retained API synthesis capability primarily in two domains: complex, high-value molecules too sophisticated for commodity replication, and a small number of commodity categories where producers such as BASF and DSM maintained competitive positions through continuous process investment.

The vitamin API market: scale, volatility, and concentration risk. The European nutraceutical ingredients market was valued at approximately USD 57.3 billion in 2025 and is forecast to exceed USD 104 billion by 2034, growing at approximately 6.9% annually. Vitamin C remains the highest-volume vitamin API consumed in Europe, with EU imports of approximately 45,000 metric tonnes per year; Germany alone imports approximately 9,000 to 10,000 MT annually. China dominates production through a small group of large-scale producers concentrated in Hebei and Henan provinces. Pricing is volatile and cyclically tied to Chinese production economics, ranging from approximately USD 3.50/kg in 2021, to USD 6–8/kg in 2022 during pandemic-driven disruption, to approximately USD 2.69/kg by September 2025.

Vitamin A and E remain among the few vitamin APIs where European manufacturing has been maintained at commercial scale, primarily by BASF’s Ludwigshafen complex. In July 2024, a major fire at the Ludwigshafen site caused BASF to declare Force Majeure on Vitamin A, Vitamin E, and carotenoid supplies — triggering a global supply shock with Vitamin A prices surging 30 to 60%. The incident was a vivid, unambiguous demonstration of the concentration risk inherent in the current European API supply structure: a single industrial fire at one of the last European producers caused immediate global shortages. CoQ10 (coenzyme Q10) is among the fastest-growing nutraceutical API segments, with a global market of approximately USD 710 million in 2024 expanding at an estimated CAGR of 10.9%; Japan (Kaneka Corporation) pioneered fermentation-based production and remains the quality benchmark. Omega-3 fatty acids (EPA/DHA, fish-oil-derived) are the highest-selling single nutraceutical ingredient category in Europe by value, with supply concentrated in Norwegian producers (BASF, Epax).

European policy response: the gap between ambition and economics. The COVID-19 pandemic exposed the depth of Europe’s API import dependency: shortages of paracetamol, antibiotics, and other essential medicines reflected supply chains that traced back to a small number of Indian or Chinese facilities, with no European fallback. The Critical Medicines Act (March 2025) establishes monitoring obligations for medicines with identified supply vulnerabilities and requires strategic stocks of designated critical APIs. The IPCEI Med4Cure — a €1 billion Important Project of Common European Interest announced in 2024 — funds greenfield and brownfield investment in European API production capacity. The most high-profile structural attempt at reshoring is EUROAPI — spun off from Sanofi in 2022 as a standalone European API manufacturer operating six production sites across France, Hungary, Germany, Italy, the UK, and the Czech Republic. The commercial reality has been challenging: EUROAPI issued profit warnings in 2023 and underwent restructuring. The honest assessment is that full reshoring of commodity API production to Europe is not economically viable at market pricing; the realistic medium-term outcome is a tiered structure — strategic stockpiling and near-shoring (Eastern Europe, India) for the most critical APIs, combined with genuine investment in the high-complexity, high-value API categories where European chemistry generates returns that commodity synthesis cannot.

The supplier landscape: who remains European at scale. Among vitamin and nutraceutical API producers, BASF SE (Germany) remains one of the most significant European participants — vitamins A, E, B2, carotenoids, and Vitamin C precursors — and the Ludwigshafen facility is being rebuilt following the 2024 fire. DSM-Firmenich (Netherlands/Switzerland, merged 2023) produces vitamins B, C, D, and E alongside omega-3 concentrate, with European production in Delft, Germany, and Switzerland. Among complex and biotechnology-derived APIs, Lonza (Switzerland) is dominant in biologic API contract manufacturing — a category growing faster than any other segment of pharmaceutical production, where European quality infrastructure, regulatory expertise, and proximity to biotechnology R&D clusters create genuine competitive advantages. For CoQ10, Japan retains the quality benchmark through fermentation-based production technology, commanding meaningful retail price premiums that justify European pharmaceutical companies’ preference for certified Japanese supply.

The supply chain resilience imperative. Across all three product categories — capsules, blister film, and APIs — the dominant structural narrative of 2020 to 2026 has been supply chain risk made visible. The combination of COVID-19 disruptions, the BASF force majeure, the Klöckner Pentaplast financial restructuring, and ongoing EU-China geopolitical tension has elevated supply chain diversification from a procurement consideration to a regulatory and strategic imperative. Pharmaceutical companies increasingly require suppliers to demonstrate dual-source qualification and geographic supply diversity as a condition of preferred vendor status. In practice, the economics of full reshoring constrain the ambition: the realistic model emerging is a tiered procurement architecture — dual qualification between a cost-competitive Asian source and a European or Indian near-shore source for critical materials; strategic inventory buffers for the highest-risk APIs; and active qualification of alternative suppliers wherever top-three supply concentration exceeds 70%. For companies sourcing capsules, this increasingly means having both a Western incumbent and a GMP-certified Asian supplier qualified and active — not as a cost-optimisation exercise but as a resilience one.

Regulatory convergence as a competitive filter. EU GMP requirements, enforced by the EMA and national competent authorities — AIFA in Italy, BfArM in Germany, ANSM in France, AEMPS in Spain — apply universally to pharmaceutical API and excipient suppliers regardless of geography. The compliance requirement is the most consequential market-access filter operating across all three categories simultaneously: for capsules, it separates certified Asian suppliers from uncertified ones; for blister film, it frames the FMD-driven serialisation investment wave; for APIs, it is the primary reason European and Japanese quality-benchmark suppliers retain commercial viability despite cost disadvantages. The EU Pharmaceutical Legislation reform package, progressing through the legislative process as of 2025–2026, will add compliance layers that tend to favour larger, better-capitalised suppliers — accelerating consolidation across all three categories.

Sustainability: different challenges, shared urgency. For hard capsules, the gelatin-to-HPMC shift carries a plant-based narrative that aligns with nutraceutical consumer positioning, even though HPMC’s environmental credentials relative to gelatin are nuanced in a full lifecycle assessment. For blister film, the challenge is acute and structural: PVC/aluminium composite packaging is not recyclable in standard streams, the PPWR 2035 review creates a defined horizon of regulatory pressure, and materials innovation (mono-material barriers, paper-based blisters) faces five-to-ten-year regulatory approval pathways. For APIs, EU REACH regulation and its planned revision will increase pressure on legacy synthetic routes using restricted substances, while Chinese API producers face growing domestic environmental regulation that is gradually raising their compliance costs — a dynamic that will modestly narrow the cost gap with European production over the decade.

Market outlook to 2030. The growth trajectory across all three categories is structurally supported by demographic ageing in Western Europe, post-pandemic elevated health consciousness, and the expansion of preventive medicine and personalised nutrition. Eastern and Central Europe — particularly Poland, Czech Republic, Hungary, and Romania — is expected to be the fastest-growing regional sub-market for all three categories through 2030, as Western European pharmaceutical companies expand generics and OTC manufacturing in lower-cost EU jurisdictions while maintaining full regulatory compliance. The hard capsule market will approach USD 580–700 million in Europe by 2030, with HPMC growing toward a 30–35% volume share; the blister film market will approach USD 7.0–7.1 billion, with cold-form Alu-Alu outpacing overall growth; the nutraceutical ingredients market will approach USD 80–104 billion. The supply-side risks that could interrupt these trajectories — geopolitical disruption to Chinese supply chains, EU regulatory tightening, energy price volatility, and sustainability-driven reformulation outpacing approval — are each known, and none is hypothetical. The question for procurement and commercial strategy teams is not whether these disruptions will occur; it is whether their organisations are positioned to absorb them when they do.

The capsule that holds a vitamin, the aluminium foil that seals a tablet, and the active molecule inside both of them represent three different industrial histories converging on the same structural reality: European pharmaceutical manufacturing excellence built its competitive position on inputs that European chemical and packaging industry leaders produced, and the gradual displacement of those producers — first to lower-cost Western competitors, then to Asian manufacturers — has created an import dependency that is now recognised as a strategic vulnerability rather than a procurement efficiency.

The reversal of that dependency is underway, partly through policy (IPCEI Med4Cure, Critical Medicines Act, PPWR) and partly through commercial logic, as reliability, quality certification, and supply chain proximity acquire pricing premiums that the lowest-cost Asian suppliers cannot compete on. The European manufacturers and Asian producers building EU-footprint positions — investing in Eastern European production, expanding European vitamin capacity, maintaining premium positions in high-barrier films — are doing so in a market where the structural case for supply proximity has never been more commercially validated.

For companies operating in pharmaceutical manufacturing, nutraceutical production, or contract packaging services, the next five years will require choices: which categories to dual-source, which suppliers to qualify beyond the incumbent, and which regulatory and sustainability pressures to anticipate rather than react to. The architecture of the medicine cabinet is invisible to the patient. It should not be invisible to the supply chain teams responsible for ensuring it works.